Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

Metsera raised $275 million in its IPO, pricing 15.3 million shares at $18 per share, exceeding its initial $15-$17 range13.

Maze Therapeutics raised $140 million, offering 8.75 million shares at $16 per share, which was the midpoint of its expected range57.

Metsera will trade under the ticker "MTSR" and is developing MET-097i, a GLP-1 receptor agonist for obesity treatment13.

Maze Therapeutics will trade under the ticker "MAZE" and is advancing MZE829, an oral APOL1 inhibitor for kidney disease57.

Both companies are expected to begin trading on the Nasdaq on January 31, 202537.

Metsera's IPO was downsized from 17.2 million shares but still met its target of raising over $275 million1.

Maze Therapeutics upsized its offering from 7.8 million to 8.75 million shares5.

Both IPOs are expected to close on February 3, 2025, subject to customary closing conditions37.

These IPOs represent significant investor interest in biotechnology companies focusing on obesity and kidney disease treatments.

The successful IPOs indicate a strong start to 2025 for the biotech sector in the public markets10.

Sources:

1. https://www.fiercebiotech.com/biotech/busy-day-biotech-ipos-metsera-maze-go-public-offerings-275m-113m

3. https://www.globenewswire.com/news-release/2025/01/30/3018515/0/en/Metsera-Announces-Pricing-of-Initial-Public-Offering.html

5. https://www.biospace.com/press-releases/maze-therapeutics-announces-pricing-of-upsized-initial-public-offering

7. https://www.globenewswire.com/news-release/2025/01/31/3018524/0/en/Maze-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

10. https://www.biopharmadive.com/news/maze-metsera-ipo-biotech-obesity-kidney/738539/